Summary

This NIH-funded study followed 94 children and young teens (average age 11) who started puberty blockers at four large US gender clinics. Over two years, their own reports of depression and emotional wellbeing, and parents' reports of behaviour, did not measurably improve. Average scores were normal from the start. The authors read this as a sign blockers probably prevented a decline, but with no comparison group that claim is untested. More than a third of depression data were missing at two years, about a third started cross-sex hormones during the study, and the results reported differ from those first planned. In 2024 the lead author told The New York Times she had delayed publishing for fear the results would be "weaponized"; they appeared as an unreviewed preprint (early version) in May 2025. It shows no measurable mental health benefit.

Key findings

• 94 νέοι ηλικίας 8 έως 16 (μέσος όρος 11· 52% γεννημένοι άνδρες· οι περισσότεροι σε πρώιμη εφηβεία) που ξεκινούσαν αναστολείς εφηβείας σε τέσσερις αμερικανικές κλινικές παρακολουθήθηκαν για 2 χρόνια.
• Οι δικές τους αναφορές για την κατάθλιψη και τη συναισθηματική υγεία και οι αναφορές των γονέων για προβλήματα δεν έδειξαν μετρήσιμη αλλαγή σε 2 χρόνια· μόνο η παραβατική συμπεριφορά μειώθηκε ελαφρά.
• Το 18% είχε μέτρια ή σοβαρή κατάθλιψη στην αρχή (16 από 88) και το 23% στα 2 χρόνια (13 από 59).
• Μόνο 59 από 94 είχαν δεδομένα κατάθλιψης στα 2 χρόνια, οπότε το 37% έλειπε.
• 11 ξεκίνησαν οιστρογόνα ή τεστοστερόνη μέσα στον πρώτο χρόνο και 20 ακόμη στον δεύτερο, οπότε το ένα τρίτο πήρε ορμόνες του άλλου φύλου κατά τη διάρκεια της μελέτης.
• 11 νέοι ανέφεραν αυτοκτονικές σκέψεις τους 6 μήνες πριν από την έναρξη και 5 στα 2 χρόνια· δεν υπήρξαν θάνατοι από αυτοκτονία.
• Οι συγγραφείς κατέληξαν ότι οι αναστολείς «πιθανώς» προλαμβάνουν την επιδείνωση της ψυχικής υγείας, αν και χωρίς ομάδα σύγκρισης η μελέτη δεν μπορούσε να το ελέγξει.
• Η έκθεση προόδου του NIH ανέμενε μειώσεις στην κατάθλιψη, το άγχος, τα συμπτώματα τραύματος, τον αυτοτραυματισμό και τις αυτοκτονικές σκέψεις, και καλύτερη εικόνα σώματος και ποιότητα ζωής· αυτές οι βελτιώσεις δεν φάνηκαν.

Abstract

BACKGROUND AND OBJECTIVES: Medical interventions for youth with gender dysphoria can include the use of gonadotropin releasing hormone analogs (GnRHas) for suppression of endogenous puberty. This analysis aimed to understand the impact of medical intervention initiated with GnRHas on psychological well-being among youth with gender dysphoria over 24 months.

METHODS: Participants were enrolled as part of the Trans Youth Care United States Study. Eligibility criteria for youth included a diagnosis of Gender Dysphoria and pubertal initiation. Youth with precocious puberty or pre-existing osteoporosis were ineligible. Youth reported on depressive symptoms, emotional health and suicidality at baseline, 6, 12, 18 and 24 months after initiation of GnRHas. Parent/caretaker completed the Child Behavior Checklist at baseline, 12 and 24 months after initiation of GnRHas. Latent Growth-Curve Models analyzed trajectories of change over the 24-month period.

RESULTS: Ninety-four youth aged 8-16 years (mean=11.2 y) were predominately Non-Hispanic White (56%), early pubertal (86%) and assigned male at birth (52%). Depression symptoms, emotional health and CBCL constructs did not change significantly over 24 months. At no time points were the means of depression, emotional health or CBCL constructs in a clinically concerning range.

CONCLUSION: Participants initiating medical interventions for gender dysphoria with GnRHas have self- and parent-reported psychological and emotional health comparable with the population of adolescents at large, which remains relatively stable over 24 months. Given that the mental health of youth with gender dysphoria who are older is often poor, it is likely that puberty blockers prevent the deterioration of mental health.

Conclusion

Participants initiating medical interventions for gender dysphoria with GnRHas have self- and parent-reported psychological and emotional health comparable with the population of adolescents at large, which remains relatively stable over 24 months. Given that the mental health of youth with gender dysphoria who are older is often poor, it is likely that puberty blockers prevent the deterioration of mental health. (Full-text conclusion: the average mental health as reported by both the youth and parents remains in a clinically non-significant range over two years.)